Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02405442 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
NCT02405442 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 187 participants.
The verdict
NCT02405442, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
Study Summary
This study will primarily evaluate the safety and efficacy of andecaliximab in adults with active Crohn's disease. The study will consist of a Double-Blind Phase of 8 weeks followed by an Open-Label Extension. Participants who complete the Double-Blind Phase will be eligible to enroll in the optional Open-Label Extension for an additional 44 weeks. Participants who complete Week 52 assessments will be eligible to enter the Extended Treatment Phase to continue treatment with andecaliximab for an additional 156 weeks.
Interventions
- DRUG Placebo
- DRUG Andecaliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2015-04-30 |
| Est. Completion | 2016-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02405442
The ClinicalTrials.gov registry entry for NCT02405442 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02405442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02405442 about?
NCT02405442 is a clinical study titled "Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease". This study will primarily evaluate the safety and efficacy of andecaliximab in adults with active Crohn's disease. The study will consist of a Double-Blind Phase of 8 weeks followed by an Open-Label Extension. Participants who complete the Double-Blind Phase will be eligible to enroll in the optiona...
What is the current status of trial NCT02405442?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2015-04-30. Estimated completion is 2016-12-22.
What interventions are being tested in trial NCT02405442?
The interventions under investigation include: Placebo (DRUG), Andecaliximab (DRUG).
Who is sponsoring clinical trial NCT02405442?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.